Drug Profile


Alternative Names: Kvaterin; MET-88; Quaterin

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator Latvian Institute of Organic Synthesis
  • Developer Grindeks; Taiho Pharmaceutical
  • Class Adjuvants; Antiarrhythmics; Cardiotonics; Ischaemic heart disorder therapies; Methylhydrazines; Propionates; Small molecules; Vasodilators
  • Mechanism of Action Gamma-butyrobetaine dioxygenase inhibitors; Partial fatty acid oxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Ischaemic heart disorders
  • No development reported Angina pectoris; Arrhythmias

Most Recent Events

  • 04 Jul 2016 Phase III development is ongoing in China
  • 30 May 2014 Phase-III clinical trials in Ischaemic heart disorders in China (PO)
  • 30 May 2014 Phase-III clinical trials in Ischaemic heart disorders in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top